- Home
- MQT vs DSGN Comparison
MQT vs DSGN Comparison
Compare MQT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQT
- DSGN
- Stock Information
- Founded
- MQT 1992
- DSGN 2017
- Country
- MQT United States
- DSGN United States
- Employees
- MQT N/A
- DSGN N/A
- Industry
- MQT Investment Bankers/Brokers/Service
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- MQT Finance
- DSGN Health Care
- Exchange
- MQT Nasdaq
- DSGN Nasdaq
- Market Cap
- MQT 218.4M
- DSGN 208.9M
- IPO Year
- MQT N/A
- DSGN 2021
- Fundamental
- Price
- MQT $10.15
- DSGN $5.95
- Analyst Decision
- MQT
- DSGN
- Analyst Count
- MQT 0
- DSGN 0
- Target Price
- MQT N/A
- DSGN N/A
- AVG Volume (30 Days)
- MQT 52.5K
- DSGN 162.2K
- Earning Date
- MQT 01-01-0001
- DSGN 11-06-2025
- Dividend Yield
- MQT 4.60%
- DSGN N/A
- EPS Growth
- MQT N/A
- DSGN N/A
- EPS
- MQT N/A
- DSGN N/A
- Revenue
- MQT N/A
- DSGN N/A
- Revenue This Year
- MQT N/A
- DSGN N/A
- Revenue Next Year
- MQT N/A
- DSGN N/A
- P/E Ratio
- MQT N/A
- DSGN N/A
- Revenue Growth
- MQT N/A
- DSGN N/A
- 52 Week Low
- MQT $8.59
- DSGN $2.60
- 52 Week High
- MQT $10.67
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- MQT 78.90
- DSGN 56.54
- Support Level
- MQT $9.47
- DSGN $5.80
- Resistance Level
- MQT $10.15
- DSGN $6.65
- Average True Range (ATR)
- MQT 0.08
- DSGN 0.48
- MACD
- MQT 0.05
- DSGN -0.06
- Stochastic Oscillator
- MQT 95.77
- DSGN 55.09
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.